(-0.03%) 5 477.00 points
(-0.06%) 38 794 points
(0.02%) 19 924 points
(0.29%) $80.56
(1.26%) $2.82
(0.20%) $2 333.70
(-0.24%) $29.32
(-0.18%) $969.20
(0.01%) $0.932
(-0.15%) $10.64
(0.06%) $0.788
(-1.86%) $86.80
Live Chart Being Loaded With Signals
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases...
Stats | |
---|---|
Šios dienos apimtis | 2.00M |
Vidutinė apimtis | 4.79M |
Rinkos kapitalizacija | 220.08M |
EPS | $-0.0878 ( Q1 | 2024-05-09 ) |
Kita pelno data | ( $-0.0700 ) 2024-08-23 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
-4.77 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.00700 (0.66%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-06-06 | Wolf Myles | Buy | 30 000 | Common Stock |
2024-06-06 | Wolf Myles | Buy | 45 000 | Stock Option (Right to buy) |
2024-06-06 | Smith Cynthia | Buy | 30 000 | Common Stock |
2024-06-06 | Smith Cynthia | Buy | 45 000 | Stock Option (Right to buy) |
2024-06-06 | Rogers Michael W | Buy | 30 000 | Common Stock |
INSIDER POWER |
---|
86.90 |
Last 97 transactions |
Buy: 10 736 838 | Sell: 781 354 |
Tūris Koreliacija
Akebia Therapeutics Inc Koreliacija
10 Labiausiai neigiamai susiję koreliacijos |
---|
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
Akebia Therapeutics Inc Koreliacija - Valiuta/Žaliavos
Akebia Therapeutics Inc Finansinės ataskaitos
Annual | 2023 |
Pajamos: | $194.62M |
Bruto pelnas: | $118.89M (61.09 %) |
EPS: | $-0.280 |
FY | 2023 |
Pajamos: | $194.62M |
Bruto pelnas: | $118.89M (61.09 %) |
EPS: | $-0.280 |
FY | 2022 |
Pajamos: | $292.60M |
Bruto pelnas: | $207.81M (71.02 %) |
EPS: | $-0.580 |
FY | 2021 |
Pajamos: | $213.58M |
Bruto pelnas: | $60.18M (28.18 %) |
EPS: | $-1.700 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Akebia Therapeutics Inc
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients. It also offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. Akebia Therapeutics, Inc. has collaboration agreements with Otsuka Pharmaceutical Co. Ltd. for the development and commercialization of vadadustat in the United States, the European Union, Russia, China, Australia, Canada, the Middle East, and other countries; and Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.